1. The Eli Lilly & Mounjaro Disruption: A New Market Era
The defining narrative of the Indian Pharmaceutical Market (IPM) in May 2026 centers on Eli Lilly and its breakthrough metabolic formulation, MOUNJARO. Following significant shifts in the incretin market—including the patent expiry of generic semaglutide in March 2026—Eli Lilly has successfully capitalized on an unprecedented wave of physician and patient demand for advanced dual GIP/GLP-1 therapies optimized for glycemic control and obesity management.
This strategic introduction has completely disrupted traditional market hierarchies:
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
